RxDoctor Payments Data

Vanessa Tilney, MD

Internal Medicine · Houston, TXNPI 1285673152

Payments from drug & device makers

$16,229in general payments, 2019–2025

Across 992 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AbbVie$2K
  • AstraZeneca$2K
  • Lilly USA, LLC$1K
  • Amgen$736
  • Boehringer Ingelheim$733
  • plus $7K from 40 others

What the payments were for

  • Food & beverage$16,215100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,229 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$99,683
Medicare patients
336
Services billed
937

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide135$177,116
JardianceEmpagliflozin84$92,697
EliquisApixaban83$89,561
MounjaroTirzepatide71$83,535
FarxigaDapagliflozin Propanediol68$76,664
TrulicityDulaglutide17$35,197
CreonLipase/Protease/Amylase11$26,786
JanuviaSitagliptin Phosphate20$24,054
XareltoRivaroxaban21$22,195
Repatha SureclickEvolocumab27$17,778
MyrbetriqMirabegron13$15,270
LinzessLinaclotide11$10,442
Tresiba Flextouch U-100Insulin Degludec18$8,543
VascepaIcosapent Ethyl14$7,507
Atorvastatin Calcium474$6,685

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,600$177,116135 claims
Lilly USA, LLCMounjaro, Trulicity$1,346$118,73188 claims
Boehringer IngelheimJardiance$733$92,69784 claims
PfizerEliquis, Paxlovid$472$90,990106 claims
AstraZenecaFarxiga$1,525$76,66468 claims
AbbVieCreon, Linzess, Synthroid$2,072$42,21594 claims
MerckJanuvia$86$24,05420 claims
Johnson & JohnsonXarelto$421$22,19521 claims
Astellas Pharma US IncMyrbetriq$579$15,27013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →